OMER: Omeros Corp. Market Cap to Revenue

Omeros Corporation maintains a monopoly in the anti-inflammatory niche thanks to unique patents on MASP-2 molecules. Currently, the R&D division is reviewing clinical data following regulatory delays while advancing early-stage research. However, the risks of registration denials for new drugs and existing debt are creating pressure. Historical P/S dynamics help assess business sales, with the current level sitting around 32.70.
Metric breakdowns and analytics for Omeros Corporation (OMER)

The stability of Omeros Corporation (OMER) is based on the commercialization of ophthalmology drugs and licensing agreements, making revenue volume a key driver of capitalization. The P/S ratio correlates the market value of the business with its annual sales, measuring the premium an investor is willing to pay per unit of revenue; meanwhile, the price/sales ratio trend allows for the identification of valuation anomalies signaling that the asset is overbought or undervalued.